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The elevated production of reactive oxygen species (ROS) in the vascular wall is
associated with cardiovascular diseases such as hypertension. This increase in oxidative
stress contributes to various mechanisms of vascular dysfunction, such as decreased
nitric oxide bioavailability. Therefore, anti-oxidants are being researched to decrease
the high levels of ROS, which could improve the microvascular dysfunction associated
with various cardiovascular diseases. From a therapeutic perspective, cerium dioxide
nanoparticles (CeO2 NP) hold great anti-oxidant potential, but their in vivo activity is
unclear. Due to this potential anti-oxidant action, we hypothesize that injected CeO2
NP would decrease microvascular dysfunction and oxidative stress associated with
hypertension. In order to simulate a therapeutic application, spontaneously hypertensive
(SH) and Wistar-Kyoto (WKY) rats were intravenously injected with either saline or
CeO2 NP (100µg suspended in saline). Twenty-four hours post-exposure mesenteric
arteriolar reactivity was assessed via intravital microscopy. Endothelium-dependent
and –independent function was assessed via acetylcholine and sodium nitroprusside.
Microvascular oxidative stress was analyzed using fluorescent staining in isolated
mesenteric arterioles. Finally, systemic inflammation was examined using a multiplex
analysis and venular leukocyte flux was counted. Endothelium-dependent dilation was
significantly decreased in the SH rats (29.68 ± 3.28%, maximal response) and this
microvascular dysfunction was significantly improved following CeO2 NP exposure
(43.76 ± 4.33%, maximal response). There was also an increase in oxidative stress in
the SH rats, which was abolished following CeO2 NP treatment. These results provided
evidence that CeO2 NP act as an anti-oxidant in vivo. There were also changes in
the inflammatory profile in the WKY and SH rats. In WKY rats, IL-10 and TNF-α were
increased following CeO2 NP treatment. Finally, leukocyte flux was increased in the SH
rats (34 ± 4 vs. 17 ± 3 cells/min in the normotensive controls), but this activation was
decreased following exposure (15 ± 2 vs. 34 ± 4 cells/min). These results indicated
that CeO2 NP may alter the inflammatory response in both SH and WKY rats. Taken
together, these results provide evidence that CeO2 NP act as an anti-oxidant in vivo and
may improve microvascular reactivity in a model of hypertension.
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INTRODUCTION
There is a growing interest in developing therapeutic
interventions that result in more precise and individualized
treatment. Engineered nanomaterials (ENM) are prime
candidates for therapeutic applications for several reasons
(Kelkar and Reineke, 2011). First, the size of ENM (≤100 nm
in at least one dimension) creates a large surface area for the
attachment of various pharmaceuticals and/or imaging agents
(Borm et al., 2006). Their small size also allows ENM to access
every bodily component via the circulation (Stapleton and
Nurkiewicz, 2014). Secondly, by altering the surface chemistry
and/or using specific ENM, they may be precisely aimed at target
areas in the body, which (in conjunction with a high surface)
reduces the dosage needed to treat certain pathologies (Roco
et al., 2010; Yu et al., 2010a). Finally, many ENM possess inherent
unique characteristics (e.g., auto-fluorescence, and anti-oxidant
activity) that can be exploited to increase their pharmaceutical
relevance (Borm et al., 2006).
Cerium dioxide nanoparticles (CeO2 NP) are one type of
ENM that are currently being investigated for their possible
therapeutic significance (Colon et al., 2009; Kim et al., 2012;
Madero-Visbal et al., 2012). CeO2 NP have catalytic activity,
which arises from the presence of two valence states (Ce3+ and
Ce4+) (Celardo et al., 2011). Due to the oxygen vacancies present
in these nanoparticles, they are able to react with surrounding
reactive oxygen species (ROS), thus introducing CeO2 NP as
a potential in vivo mimetic for endogenous anti-oxidants like
superoxide dismutase (Heckert et al., 2008; Xu and Qu, 2014;
Dunnick et al., 2015).
Like many pharmaceuticals, CeO2 NP research has produced
conflicting results about the efficiency of its potential anti-
oxidant activity. In vitro analysis has shown an increase in ROS
generation and inflammation following CeO2 NP co-incubation;
however, other studies with cardiac progenitor and endothelial
cells have shown a decrease in both these parameters (Park et al.,
2008; Gojova et al., 2009; Horie et al., 2011; Wingard et al., 2011;
Pagliari et al., 2012). The in vivo analysis of these nanoparticles is
evenmore complex. Experimentally, injected CeO2 NPhave been
shown to decrease tissue damage, which is commonly associated
with radiation treatments and strokes (Colon et al., 2009; Kim
et al., 2012). Despite these promising results, CeO2 NP injected
into young healthy rats may have detrimental effects that result in
microvascular dysfunction (Minarchick et al., 2015). Currently,
it is unclear if the potential positive effects of CeO2 NP are
pathology specific. Furthermore, it is also unknown how CeO2
NP specific alterations in ROS production affect microvascular
function.
Hypertension affects one out of three Americans and is a
leading factor in the development of cardiovascular disease
(Nwankwo et al., 2013). This pathology is associated with
microvascular dysfunction that is, at least partially, attributed
to increased ROS generation due to chronic inflammation,
mitochondrial dysfunction, and/or nitric oxide synthase (NOS)
uncoupling (Félétou and Vanhoutte, 2006; Brito et al., 2015). In
addition to decreasing vasoactive factors directly, the elevated
levels of ROS are capable of increasing steroid hormone
production, which can impair NOS activity and prostaglandin
formation, which increase the risk of organ damage (Suzuki
et al., 1995). The influence of ROS on microvascular function has
led to the investigation of anti-oxidants as potential therapeutic
treatments (Brito et al., 2015). If the anti-oxidant potential of
CeO2 NP were better understood, this ENM could be developed
as a treatment to decrease high levels of ROS, which may
ultimately reduce the microvascular dysfunction associated with
various diseases such as hypertension.
Therefore, the purpose of this study was to assess the in vivo
anti-oxidant potential of CeO2 NP in a high ROS environment,
specifically hypertension. Previous in vitro studies have shown
that in the presence of elevated ROS CeO2 NP act as an anti-
oxidant and can decrease ROS (Minarchick et al., 2015). Based
on these results, we hypothesize that following injection CeO2
NP will act as an anti-oxidant and reduce the oxidative stress and
microvascular dysfunction that is associated with hypertension.
This potential outcome may provide valuable information about
the anti-oxidant activity of CeO2 NP, which is pivotal for it to
be developed as an anti-oxidant treatment for cardiovascular
diseases.
METHODS AND MATERIALS
Cerium Dioxide Nanoparticle (CeO2 NP)
Production and Characterization
CeO2 NP powders were synthesized by a hydrothermal process
as previously described (Minarchick et al., 2013). Briefly, cerium
(IV) ammonium nitrate (99+% Alfa Aesar, Ward Hill, MA)
was added to de-ionized water (H2O) and this solution was
added drop-wise into a basic solution of tetramethylammonium
hydroxide pentahydrate and de-ionized H2O. The pH of the
dispersion was altered to ∼10.5 with ammonium hydroxide
and was maintained throughout the reaction. The dispersion
was placed in a 300ml Autoclave Engineers EZE-Seal autoclave
(Erie, PA) at 240◦C for 1 h. Once removed from the autoclave,
the dispersion was placed into a centrifuge and the liquid was
removed and replaced with ethanol. After the washing step,
the dispersion was dried at 60◦C overnight and sieved through
a 200 mesh screen for characterization. The nanoparticles
were previous characterized (Minarchick et al., 2013). Briefly,
the CeO2 NP had a surface area of 81.36m
2/g measured
by Micromeritics ASAP 2020 (Norocross, GA). JEOL JEM-
2100 High Resolution Transmission Electron Microscope (TEM)
(Peabody, MA) determined the primary particle size (∼2–
4 nm) and shape (spherical). The average agglomerate size in
saline (Normosol, Nospira Inc., Lake Forest, IL) and 5% fetal
bovine serum (FBS) was 191 nm as determined by dynamic light
scattering via a Malvern Zetasizer version 7.01 (Westborough,
MA). Finally, the valence state of the CeO2 NP was ∼81% Ce
4+
and∼19%Ce3+ determined by x-ray photoelectron spectroscopy
(PHI 5000 Versaprobe XPS, Chanhassen, MN).
Experimental Animals
Male spontaneously hypertensive (SH) rats and Wistar-Kyoto
(WKY) rats (∼10 weeks old) were purchased from Harlan
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laboratories (Indianapolis, IN). SH rats were studied because
they are a well-established model of microvascular dysfunction
and excess local ROS production (Bakker et al., 2014; Brito
et al., 2015). WKY rats were used as a normotensive control
for the SH in these experiments (Okamoto et al., 1967). The
rats were housed at the West Virginia University (WVU)
Health Sciences Center Vivarium, in laminar flow cages, under
controlled humidity and temperature, with a 12 h light/dark
cycle, and food and water were provided ad libitum. The animals
were acclimated for a minimum of 2 days prior to use. TheWVU
Institutional Animal Care and Use Committee atWVU approved
all procedures.
CeO2 NP Solution Preparation and
Exposure
The animals used in these studies were injected with a 100µg
dose (∼0.42mg/kg) of CeO2 NP 24 h prior to experimental
assessments. To prepare this dose, a stock suspension was
prepared daily containing 1.1mg of dry CeO2 NP powder
and 10ml of Normosol with 5% FBS to reduce agglomeration
(Minarchick et al., 2013, 2015). The CeO2 NP were vortexed for
5min and then sonicated on ice for an additional 5min. Rats were
lightly anesthetized with isoflurane gas (5% induction, 2–3.5%
maintenance). Rats were divided into four groups and were
intravenously injected in the tail vein with a 900µl bolus dose
of saline (WKY-Sham, SH-Sham) or CeO2 NP stock suspension
(WKY-CeO2 NP, SH-CeO2 NP) using a 23G needle. The final
dose was 100µg per rat. This dose was predetermined to
cause a 50% impairment in microvascular function in previous
experiments and was also within the functional dose range for
CeO2 NP (Kim et al., 2012; Minarchick et al., 2015)Rats were
monitored after treatment until they regained consciousness.
Intravital Microscopy Preparation
Animals were anesthetized with Inactin [100mg/kg,
intraperitoneal (ip) injection] and placed on a heating pad
to maintain a 37◦C rectal temperature. The trachea was
intubated to maintain a patent airway, and the right carotid
artery was cannulated to monitor mean arterial pressure (MAP)
and heart rate. A loop of the small intestine (ileum) was surgically
exteriorized. Once exteriorized, two small incisions 6–10 cm
apart were made along the intestinal wall using thermal cautery
and the chyme was flushed from the lumen through the incisions.
The ileum was then carefully placed over a clear pedestal, and
gently secured so that the mesenteric circulation was at its
in situ length. Throughout the preparation and experiment,
the exposed mesentery was continuously superfused with an
electrolyte solution (119mMNaCl, 25mMNaHCO3, 6mM KCl,
and 3.6mM CaCl2) that was warmed to 37
◦C and equilibrated
with 95% N and 2–5% CO2 (pH 7.35–7.40). Intestinal motility
was suppressed using isoproterenol hydrochloride (10mg/l,
Sigma-Aldrich, St. Louis MO) and phenytoin (20mg/l, Sigma-
Aldrich, St. Louis MO). At these concentrations, isoproterenol
and phenytoin have no significant effect on arteriolar tone
(Bohlen et al., 1978). The superfusate rate was maintained at
4–6ml/min to minimize equilibration with atmospheric oxygen
(Boegehold and Bohlen, 1988). The animal preparation was then
transferred to the stage of an intravital microscope coupled to a
charge-coupled device (CCD) video camera. Observations were
made with a 20x water immersion objective. Video images were
displayed on a high-resolution color video monitor and recorded
for off-line analysis. During analysis, arteriolar inner diameters
were measured with a video caliper and one to three arterioles
were studied per rat.
Microvascular Analysis
Arteriolar endothelium-dependent dilation was evaluated using
acetylcholine (ACh, 0.25M). ACh was iontophoretically applied
to individual 5th order arterioles (20, 100, and 150 nA). Glass
micropipettes were beveled at a 23–25◦ angle with 2–4µm inner
diameter tip and filled with ACh (Nurkiewicz et al., 2004). The
pipette tip was placed in light contact with the arteriolar wall and
a current programmer (Model 260;World Precision Instruments,
New Haven, CT) was used to deliver continuous ejection
currents (2min). A recovery period (at least 2min) followed each
application. The ACh response determination was repeated in the
presence of several chemical interventions which were applied
via syringe pump (0.4ml/min) into the superfusate delivery
line for 30min. The mesenteric loop was incubated with NG-
monomethyl-L-arginine (L-NMMA, 10−4 M), a NOS inhibitor,
to assess the influence of NO. Incubation with indomethacin
(INDO, 10−5 M), a cyclooxygenase (COX) inhibitor, was
used to assess the influence of COX products. The mesentery
was also incubated with 2,2,6,6-tetramethylpiperidine-N-oxyl
(TEMPOL, 10−4 M), a superoxide dismutase mimetic, and
catalase (50 units/ml), a hydrogen peroxide scavenger, to assess
the influence of ROS. All four chemical interventions (L-NMMA,
INDO, TEMPOL, and catalase) were applied to the mesentery
to determine influence of NO, COX products, and ROS
simultaneously. Vascular smooth muscle responsiveness to NO
was assessed using sodium nitroprusside (SNP, 0.05 M). SNP was
iontophoretically applied to arterioles as previously described
(10, 50, and 150 nA) (Nurkiewicz et al., 2004). Microvascular
reactivity assessments and ejection currents were randomized
and two to three assessments were completed per rat. At the end
of each experiment, adenosine (ADO, 10−4 M) was added to the
superfusate via syringe pump to determine the passive diameter
of each arteriole studied.
Finally, leukocyte flux was assessed in mesenteric paired
venules to quantify potential microvascular inflammation.
Leukocytes that were either stationary or moving but maintained
consistent contact with the venular wall for at least 200µm were
counted for 1min in each venule studied.
Oxidative Stress Analysis
A separate subset of animals (∼10 weeks old) was used
to determine changes in microvascular oxidative stress via
fluorescent analysis. SH and WKY rats were exposed to
either saline or CeO2 NP as previously described. Twenty-
four hour post-exposure, the animals were anesthetized with
Inactin (100mg/kg, ip injection) and were placed on a heating
pad to maintain a 37◦C rectal temperature. The right carotid
artery was cannulated to acquire blood for subsequent cytokine
analysis (see Section Pro-inflammatory Cytokine Analysis). The
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mesentery was removed and placed in a dissecting dish with
physiological salt solution (PSS) maintained at 4◦C (Minarchick
et al., 2015). Mesenteric arterioles (4th and 5th order) were
isolated, transferred to a vessel chamber, cannulated between
two glass pipettes, and tied with silk sutures (Living Systems
Instrumentation, Burlington, VT). In the absence of light,
dihydroethidium (DHE, 10−4 M) was intraluminally infused for
20min followed by a 20min wash with PSS to remove excess
DHE. Prior to imaging, the arterioles were pressurized to 80mm
Hg using a servo control system (Sun et al., 1992). The vessel
chamber was placed on anOlympus BX51WI uprightmicroscope
for imaging. The arteriole was first imaged briefly under
traditional bright field settings. The arteriole was illuminated
with a mercury lamp for 1 s with the appropriate excitation and
emission filters for detection of ethidium bromide fluorescence
(480–550 nm bandpass, 590 nm barrier) and hydroethidine
fluorescence (330–385 nm bandpass, 590 nm barrier). DHE was
used because it easily permeates cell membranes and can be
oxidized by ROS to form ethidium bromide which intercalates
into nuclear DNA (Morgan et al., 1979; Benov et al., 1998).
ROS-associated fluorescence was quantified in the arteriolar
wall. A user-defined region of interest (ROI) box (10 × 100µm)
was placed vertically on the endothelial cell layer of the bright
field image. It was previously determined that the mesenteric
arteriolar wall thickness was ∼13µm; therefore, the ROI box
encompassed the entire endothelial cell layer and most of
the vascular smooth muscle layer. The images were analyzed
using open access imaging software (ImageJ). The hydroethidine
image represented background and non-specific fluorescence,
therefore in order to analyze only fluorescence which had been
intercalated into the DNA this fluorescence was removed from
the ethidium bromide image. The ROI was superimposed on the
resulting image in order to acquire the mean fluorescence of the
arteriole. Total fluorescence intensity was calculated as average
fluorescence intensity per pixel x surface area.
Pro-inflammatory Cytokine Analysis
The blood collected from the SH and WKY rats was centrifuged
(1100 × g) to separate the blood components. The plasma
was collected, flash frozen in liquid nitrogen, and stored in
a −80◦C freezer until analysis. A pro-inflammatory cytokine
multi-spot assay was completed per manufacturer’s directions
(MesoScale Diagnostics, Rockville, MD). The pro-inflammatory
cytokines assessed were: interferon gamma (IFN-γ), interleukins-
1 beta, 4, 5, 6, 10 and 13 (IL-1β, IL-4, IL-5, IL-6, IL-10, and
IL-13), tumor necrosis factor alpha (TNF-α) and keratinocyte
chemoattractant/human growth-regulated oncogene (KC/GRO).
Equations: Basal tone was calculated by the following
equation,
Basal Tone (%) = [(DM − DBD)/DM]× 100,
where DBD is the baseline diametermeasured prior to any current
application, and DM is the passive diameter recorded in the
presence of ADO. The experimental responses to ACh and SNP
are expressed using the following equation:
Diameter (Percent Maximal Response) =
[DSS − DBD)/(DM − DBD)]× 100,
where DSS is the maximal diameter recorded at each current.
Statistics
Data are expressed as means ± standard error (SE). Point-
to-point differences in the dose-response determinations were
evaluated using Two-Way repeated measures analysis of variance
(ANOVA) with a Student-Newman-Keuls post-hoc analysis
when significance was found. Statistical differences in the
slopes of the dose-response determinations were determined by
linear regression analysis. The animal characteristics, arteriole
characteristics, oxidative stress, and pro-inflammatory cytokine
results were analyzed using anOne-WayANOVAwith a Student-
Newman-Keuls post-hoc analysis when significance was found.
All statistical analysis was completed with SigmaPlot 11.0 (San
Jose, CA) and GraphPad Prism 5 (San Diego, CA). Significance
was set at p ≤ 0.05, n is the number of arterioles, and N is the
number of animals.
RESULTS
Animal and Arteriolar Characteristics
There were no significant changes in age or heart rate between the
four groups (Table 1). MAP and heart weight were significantly
increased in the SH-Sham and SH-CeO2 NP groups compared
to the normotensive WKY groups (Table 1). These findings are
consistent with SH rat characteristics. There was also a significant
increase in body weight in the SH-CeO2 NP group compared
to the WKY groups (Table 1). Finally, there were no observed
differences in starting arteriolar diameter, maximal diameter,
or basal tone between the four groups (Table 2). These results
indicate that CeO2 NP injection exposure does not influence
blood pressure or arteriolar tone, when comparing the WKY and
SH groups.
Endothelium-dependent Dilation
Endothelium-dependent dilation was significantly impaired in
the SH-Sham group (29.68 ± 3.28%, maximal response)
compared to the WKY groups (53.92 ± 4.22%) (Figure 1).
Following the 100µg injection of CeO2 NP, there was a
significant augmentation in endothelium-dependent dilation in
the SH-CeO2 NP (43.76 ± 4.33%) compared to the SH-Sham
group (29.68 ± 3.28%) (Figure 1). However, this dilation was
still significantly impaired compared to the WKY-Sham group
(53.92 ± 4.22%) (Figure 1). This data provides evidence that
the injected CeO2 NP partially improve the microvascular
dysfunction associated with hypertension.
Endothelium-independent Dilation
Endothelium-independent dilationwas not impaired in the SH or
WKY groups (Figure 2). This indicates that CeO2 NP injection
exposure and hypertension, either alone or together, do not
impair arteriolar vascular NO smooth muscle sensitivity.
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TABLE 1 | Animal characteristics.
Group N Age (wks) Weight (g) Heart weight (g) MAP (mm Hg) Heart rate (beats/min)
WKY-Sham 22 10.48±0.30 230.5± 5.99 0.97± 0.03 66.25± 2.33 446.20±25.03
WKY-CeO2 NP 19 10.42±0.18 226.7± 3.73 0.93± 0.02 69.29± 2.23 471.24±7.21
SH-Sham 24 10.08±0.32 245.7± 6.20 1.12± 0.03*† 113.33± 5.37*† 427.83±18.49
SH-CeO2 NP 24 10.17±0.33 253.0± 5.41*
† 1.14± 0.04*† 106.66± 5.27*† 494.37±12.69
Values are means ± SE; N, number of animals; MAP, mean arterial pressure.
*p ≤ 0.05 vs. WKY-Sham; †p ≤ 0.05 vs. WKY-CeO2 NP.
TABLE 2 | Arteriole characteristics.
Group N Starting Maximal Basal
diameter (µm) diameter (µm) tone (%)
WKY-Sham 42 59.35 ± 2.67 88.00 ± 3.40 32.75 ± 1.25
WKY-CeO2 NP 40 59.04 ± 2.65 92.60 ± 3.65 35.42 ± 1.53
SH-Sham 58 57.44 ± 2.30 85.81 ± 3.18 32.82 ± 1.16
SH-CeO2 NP 50 60.21 ± 2.65 96.80 ± 4.08 37.02 ± 1.49
Values are means ± SE; n, number of arterioles.
FIGURE 1 | ACh-induced vasodilation was impaired in arterioles from
SH-Sham animals but was significantly improved in the SH-CeO2 NP
group compared to the SH-Sham (n = 12–29). The gray mark represents
the maximal dilation observed during incubation with ADO at the end of the
experiment. *p ≤ 0.05 vs. WKY-Sham, †p ≤ 0.05 vs. WKY-CeO2 NP,
‡p ≤ 0.05 vs. SH-Sham.
Contribution of NO, COX products, and
ROS to ACh-induced Vasodilation
The role of NO in ACh-induced vasodilation was assessed
during incubation with L-NMMA. Incubation of the mesentery
with L-NMMA significantly reduced vasodilation in response
to ACh, both in terms of the overall slopes and at the highest
ejection current, in the WKY-Sham and WKY-CeO2 NP groups
(53.92 ± 4.22%, and 56 ± 6.13%, respectively vs. 11.86 ±
9.89%, and 25.81 ± 5.08% during incubation) (Figures 3A, 4A).
Additionally, there was a significant improvement in dilation
in the SH-Sham during incubation with L-NMMA (29.68 ±
3.28% vs. 50.18 ± 8.09% during incubation), but there was
no improvement in arteriolar dilation during incubation in the
SH-CeO2 NP group (Figure 4A).
The role of COX products were assessed during incubation
with INDO. There was also a significant impairment in
FIGURE 2 | Vascular smooth muscle responsiveness to NO was not
impaired in the Sham groups or following CeO2 NP exposure
(WKY-CeO2 NP and SH-CeO2 NP groups; n = 9–19). The gray mark
represents the maximal dilation observed during incubation with ADO at the
end of the experiment.
arteriolar reactivity, in regards to the overall slopes and at
the highest ejection current, during incubation with INDO
in the WKY-Sham and WKY-CeO2 NP groups (53.92 ±
4.22%, and 56 ± 6.13%, respectively vs. 27.06 ± 4.84%, and
13.12 ± 4.28% during incubation) (Figures 3B, 4B). There
was no change in vasodilation during INDO incubation in the
SH-Sham group (Figure 4B). Finally, there was a significant
increase in vasodilation in the SH-CeO2 NP during INDO
incubation (43.76± 4.33% vs. 70.73± 7.92% during incubation)
(Figure 4B).
Local ROS was scavenged during simultaneous incubation
with TEMPOL and catalase. There was no change in arteriolar
vasodilation during TEMPOL and catalase incubation in
the WKY-Sham, WKY-CeO2 NP, and SH-CeO2 NP groups
(Figures 3C, 4C). There was a significant increase in the response
to ACh in the SH-Sham group during incubation with these
exogenous anti-oxidants (29.68 ± 3.28% vs. 49.62 ± 7.86%
during incubation) (Figure 4C).
Finally, arteriolar dilation was assessed during co-incubation
with all four chemical interventions. In regards to the overall
slopes and the highest ejection current, there was significant
decrease in arteriolar reactivity in the WKY-Sham and WKY-
CeO2 NP 53.92± 4.22%, and 56± 6.13%, respectively vs. 7.08±
11.26%, and 15.82± 1.50% during incubation) (Figures 3D, 4D).
In the SH groups, there was no significant changes in arteriolar
vasodilation in the SH-Sham group, but there was a significant
increase in dilation in the SH-CeO2 NP group (43.76 ± 4.33%
vs. 72.33 ± 6.26% during incubation) (Figure 4D). Overall,
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FIGURE 3 | The line graphs are the arterioles overall response to the various chemical interventions. (A) The role of NO was assessed during incubation
with L-NMMA (n = 14–18). This incubation resulted in a significant difference in the overall slopes of the dose-response determination within the WKY groups only. (B)
The role of COX products was assessed during incubation with INDO (n = 9–14). This incubation resulted in a significant difference in the overall slopes of the
dose-response determination within the WKY groups only. (C) Local ROS was scavenged during incubation with TEMPOL and catalase (n = 6–18). This incubation
resulted in no changes in the overall slopes of the dose-response determination in any of the four treatment groups. (D) ACh-induced vasodilation was assessed
during co-incubation with the four chemical interventions (n = 10–15). This incubation resulted in a significant difference in the overall slopes of the dose-response
determination within the WKY groups only. The gray mark represents the maximal dilation observed during incubation with ADO at the end of the experiment. The
brackets indicated significant differences in the overall slopes of the dose-determination. *p ≤ 0.05 vs. WKY-Sham, †p ≤ 0.05 vs. WKY-CeO2 NP.
these data provide initial evidence that there are differential
contributions of NO, COX products, and ROS to the observed
vasodilation after CeO2 NP injection exposure in the SH rats.
The increase in microvascular reactivity during TEMPOL and
catalase incubation in the SH-Sham group (which was similar to
the SH-CeO2 NP group), provides evidence that CeO2 NP may
act as an anti-oxidant in vivo.
Microvascular Oxidative Stress
There was a significant increase in microvascular oxidative
stress in the SH-Sham group compared to the WKY groups
(Figures 5A,B). The level of oxidative stress in the SH rats was
significantly decreased following CeO2 NP exposure and the level
of oxidative stress in the SH-CeO2 NP group was similar to the
WKY-Sham group (Figures 5A,B). There were also no significant
differences between the WKY-Sham and WKY-CeO2 NP groups
(Figures 5A,B). Taken together, these results provide evidence
that CeO2 NP have anti-oxidant activity in vivo.
Systemic Inflammation and Biomarkers
Venular leukocyte flux was assessed in all four groups. There
was a significant increase in leukocyte flux in the SH-Sham
group compared to the WKY-Sham (34 ± 4 vs. 17 ± 3
cells/min), and WKY-CeO2 NP (34 ± 4 vs. 21 ± 2 cells/min)
groups (Figure 6A). This flux was significantly decreased in
the SH animals following exposure to CeO2 NP (15 ± 2 vs.
34 ± 4 cells/min) (Figure 6A). There was also no change in
leukocyte flux between the WKY-Sham and WKY-CeO2 NP
groups (Figure 6A). Pro-inflammatory cytokines were analyzed
in harvested plasma. There were no significant differences in
IFN-γ, IL-4, IL-5, IL-6, IL-13, and KC/GRO between the groups
(data not shown). There was a significant increase in IL-10 and
TNF-α in the WKY-CeO2 NP group compared to the other three
groups (IL-10: 20.60± 4.92 pg/ml vs. 10.24± 1.09 pg/ml, average
of WKY-Sham, SH-Sham, and SH-CeO2 NP groups; TNF-α:
12.12 ± 1.38 pg/ml vs. 6.9 ± 0.45 pg/ml, average of WKY-Sham,
SH-Sham, and SH-CeO2 NP groups) (Figures 6B,C). Finally,
there was a decrease in IL-1β in the SH-Sham and SH-CeO2
NP groups compared to both WKY groups (1.58 ± 1.03 pg/ml
vs. 39.64 ± 11.37 pg/ml, average of WKY-Sham and WKY-
CeO2 NP groups) (Figure 6D). Taken together these results
provide evidence that injected CeO2 NP may alter inflammatory
signaling pathways in both normotensive and hypertensive
animals.
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FIGURE 4 | The bar graph is the dilation that was observed at 150 nA for each animal group in the presence of the selected chemical intervention. (A)
The role of NO was assessed during incubation with L-NMMA (n = 14–18). This incubation resulted in a significant decrease in arteriolar vasodilation in the WKY
groups. There was a significant increase in vasodilation during incubation in the SH-Sham group but there was no change in ACh-induced dilation in the SH-CeO2 NP
group. (B) The role of COX products was assessed during incubation with INDO (n = 9–14). This incubation resulted in a significant decrease in arteriolar vasodilation
in the WKY groups. There was no change in vasodilation in the SH-Sham group, but there was a significant increase in vasodilation following CeO2 NP (SH-CeO2
NP). (C) Local ROS was scavenged during incubation with TEMPOL and catalase (n = 6–18). This incubation resulted in no change in arteriolar vasodilation in the
WKY groups and the SH-CeO2 NP group. There was increase in vasodilation in the SH-Sham group during incubation. (D) ACh-induced vasodilation was assessed
during co-incubation with the four chemical interventions (n = 10–15). This incubation resulted in a significant decrease in arteriolar vasodilation in the WKY groups.
There was no change in vasodilation in the SH-Sham group but there was a significant increase in vasodilation following CeO2 NP (SH-CeO2 NP). The open bars
represent responses to ACh in the presence of a chemical mediator. *p ≤ 0.05 vs. WKY-Sham, †p ≤ 0.05 vs. WKY-CeO2 NP,
‡p ≤ 0.05 vs. SH-Sham, ∧p ≤ 0.05 vs.
SH-CeO2 NP.
DISCUSSION
To our knowledge, this is the first study to investigate the
in vivo anti-oxidant potential of CeO2 NP in a hypertensive
animal model. The first major finding of this study is that CeO2
NP have anti-oxidant potential in vivo resulting in decreased
microvascular dysfunction and oxidative stress that is associated
with hypertension. The second finding of this study is that
there were changes in leukocyte adhesion/rolling and cytokine
expression, which indicated that CeO2 NP might influence
thrombosis risk and inflammation.
Intravenously injected CeO2 NP significantly reduced the level
of oxidative stress in the SH rats, which contributed to decreased
microvascular dysfunction. This finding supports the notion that
CeO2 NP act as an anti-oxidant, and this finding is corroborated
by numerous studies (Colon et al., 2010; Estevez et al., 2011;
Kim et al., 2012). Despite this positive result, previous studies
have shown a decrease in vascular function following CeO2 NP
exposure (Wingard et al., 2011; Minarchick et al., 2015). These
disparate effects may be due to changes in the basal level of ROS
and the animal model.
SH rats have an increased basal level of ROS, that was not
present in the Sprague-Dawley rats that were used in previous
studies (LeBlanc et al., 2010). An increase in ROS generation
is also observed during radiation treatments and stroke, where
these ENM were shown to be beneficial in a therapeutic capacity.
This conceptual need for an increased basal level of ROS is also
supported in vitro. Cardiac progenitor cells and cardiomyocytes
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FIGURE 5 | (A) Representative ethidium bromide images indicating an increase in oxidative stress in the SH-Sham group. (B) Quantitative analysis of the ethidium
bromide images revealed a significant increase in vascular oxidative stress in the SH-Sham group that was reduced in the SH-CeO2 group (n = 5–7). These levels
were similar to the WKY-Sham and WKY-CeO2 NP groups. *p ≤ 0.05 vs. WKY-Sham,
‡p ≤ 0.05 vs. SH-Sham.
were protected fromhigh ROS levels whenCeO2 NPwere present
(Niu et al., 2011; Pagliari et al., 2012). Furthermore, there were
not high initial levels of ROS production in studies that reported
an increase in ROS following CeO2 NP exposure (Park et al.,
2008; Horie et al., 2011). When taken together these studies
support the hypothesis that CeO2 NP work optimally as an anti-
oxidant when there are elevated levels of ROS prior to or in
conjunction with exposure.
In addition to the potential changes in ROS, the selected
animal model may also affect the lack of microvascular influences
following CeO2 NP in the WKY rats. Exposures to ENM
and particulate matter have yielded different results in various
strains of animals, which indicated that genetic background
may play a vital role in determining the in vivo effects of
nanomaterials (Gottipolu et al., 2009; Wingard et al., 2011).
Both the WKY and SH animals are inbred strains compared
to the outbred Sprague-Dawley rat used in other studies with
CeO2 NP. Genetic modifications have been shown to alter the
effects of ENM exposure (Wingard et al., 2011). CeO2 NP
exposed mice have an increase in pulmonary inflammation and
vascular dysfunction; however, when these mice were genetically
modified to knockout mast cell production the inflammatory and
vascular effects were absent (Wingard et al., 2011). Therefore, it
is reasonable to speculate that genetic differences between the
WKY, SH, and Sprague-Dawley rat lineages may contribute to
the differences in the observed microvascular reactivity. Further
studies are required to investigate potential genetic differences
and their influence on the cardiovascular outcomes following
ENM exposure.
Finally, the experimental techniques utilized in various
vascular function assessments may also have contributed to
the differential microvascular effects observed in this and
other studies (Wingard et al., 2011; Minarchick et al., 2015).
Previous microvascular assessments were completed using
pressure or wire myography. These techniques allowed for
the determination of specific influences of certain agonists
without the confounding influences of blood flow and autonomic
innervation (Minarchick et al., 2015). However, the vascular
assessments in this manuscript were conducted using intravital
microscopy to determine if the observations from previous
experiments persisted in the whole animal. Therefore, the lack of
overt endothelium-dependent and -independent microvascular
dysfunction in the WKY rats could be due in part to
the activation of compensatory mechanisms, sympathetic
stimulation, and/or blood flow, which may hide underlying
microvascular dysfunction.
Despite the partial improvement inmicrovascular dysfunction
after exposure, CeO2 NP could not completely restore normal
microvascular function in the SH animal model (Figure 1). This
lack of an overall improvement could be due to arachidonic acid
(AA) metabolism via COX. This study provides evidence that
CeO2 NP exposure results in an apparent shift between NOS and
COX activity, resulting potentially in increased prostaglandin
production. Furthermore, the changes in AA signaling appear to
be unique to the CeO2 NP exposure in the SH animal model.
An increase in prostaglandin production can affect microvascular
reactivity by influencing both vasodilation and vasoconstriction.
Based on improved vasodilation during INDO incubation in
the SH-CeO2 NP animals, it can be speculated that CeO2 NP
exposure increases thromboxane A2 activity, which would result
in vasoconstriction (Figures 3, 4). This increased influence on
vasoconstriction could prevent the arterioles from fully dilating
in response to ACh. In addition to potential thromboxane A2
alterations, a potential increase in arteriolar vasoconstriction
could be due to changes in autonomic regulation, which maybe
from changes in sympathetic stimulation. It should also be
noted there was an increase in dilation during incubation
with L-NMMA in the SH-Sham animals. The source of this
improved dilation is unknown, but may be linked to change in
signaling in the hypertensive model, including NOS uncoupling,
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FIGURE 6 | (A) Leukocyte flux was assessed in venules during intravital microscopy. There was a significant increase in leukocyte flux in the SH-Sham group, which
was decreased following CeO2 NP exposure (n = 12–15). (B) Plasma IL-10 levels were significantly increased in the WKY-CeO2 NP, but not in the other three groups
(N = 7). (C) Plasma TNF-α levels were significantly increased in the WKY-CeO2 NP, but not in the other three groups (N = 6–7). (D) Plasma IL-1β levels were
significantly decreased in the SH-Sham and SH-CeO2 NP groups, but were unaltered in the WKY-CeO2 NP group (N = 6–7). *p ≤ 0.05 vs. WKY-Sham,
†p ≤ 0.05 vs.
WKY-CeO2 NP,
‡p ≤ 0.05 vs. SH-Sham, ∧p ≤ 0.05 vs. SH-CeO2 NP.
increased prostacyclin production and improved endothelium-
derived hyperpolarizing factor signaling (Nishikawa et al., 2000;
Parkington et al., 2008). Additional studies will be needed to
determine the influence of CeO2 NP on AA signaling, COX
activation, and autonomic regulation.
This study provides promising evidence of the in vivo anti-
oxidant potential of CeO2 NP; however, it is currently unclear
if CeO2 NP are operating at their maximal efficiency in vivo.
One of the primary factors that could affect the cardiovascular
outcomes of CeO2 NP (and ENM in general) is the dose. The dose
used in this study was ∼0.42mg/kg based on an average animal
weight of 240 g. This dose was on the lower end of the published
effective doses (0.4–0.7mg/kg) used to protect mice from stroke
damage (Kim et al., 2012). Therefore, it is reasonable to speculate
that increasing the dose may improve CeO2 NP anti-oxidant
effectiveness in hypertensive animals. Dose refinement could
potentially result in a further improvement in microvascular
function and decreased oxidative stress. This need for further
dose refinement also highlights a limitation of this study. It
was not possible to determine the amount of CeO2 NP that
accumulated within the vascular wall; therefore, it is unclear at
this time if the observed results are due to direct or indirect
interactions with CeO2 NP. Independent of direct or indirect
effects, understanding the cardiovascular influences, particularly
in regards to the effective dose, is vital if CeO2 NP are to be
developed as a pharmaceutical agent. Additionally, the effective
dose needs to be better understood because research has shown
that higher concentrations of CeO2 NP may result in decreased
anti-oxidant activity and an increase in pro-oxidant activity
(Horie et al., 2011). This shift in activity highlights the need to
investigate various doses within a model, and additional dosing
paradigms will need to be tested to explore the full potential of
CeO2 NP to improve the microvascular dysfunction associated
with hypertension.
Another factor that may influence the efficiency of CeO2 NP
anti-oxidant activity is the primary size of the nanoparticles.
The ENM used in this study and in another stroke study had
a primary size of 2–4 nm; however, studies that used larger
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ENM (>20 nm) have been associated with an increase in ROS
generation as opposed to a decrease (Park et al., 2008; Kim
et al., 2012). This difference in the cellular effects has also
been observed with other ENM. Silver nanoparticles with a
diameter <40 nm had increased cell permeability and toxicity vs.
their larger counterparts (>40 nm) (Sheikpranbabu et al., 2010;
Trickler et al., 2010). This not only illustrates the importance
of characterizing the size of the ENM used, but also how a
small change in ENM size can alter both their physiochemical
characteristics and their cellular and cardiovascular effects.
The proposed anti-oxidant activity is most likely connected
to the valence states (Ce3+ and Ce4+) that are present in CeO2
NP. Both valence states may react with any free radical, but
research has shown that depending on the valence state this
ENM will preferentially react with various free radicals. Under
in vitro conditions, Ce3+ preferentially reacts with the superoxide
and Ce4+ reacts with NO (Xu and Qu, 2014). The CeO2 NP
used in this study were ∼19% Ce3+ and 81% Ce4+ indicating
they may react more readily with NO; however in this study
CeO2 NP exposure did not appear to impair NO bioavailability.
This apparent lack of NO scavenging may be due to changes in
the valence state of CeO2 NP following exposure; however, it is
currently unknown to what extent the valence state of CeO2 NP
is modified following in vivo exposure (Hayes et al., 2002).
CeO2 NP exposure has also been associated with changes
in inflammation. Similar to this study, others have shown an
increase in pro-inflammatory cytokines, changes in the leukocyte
flux, and inflammatory NOS expression following in vivo CeO2
NP exposure, but these results are often inconsistent (Hirst
et al., 2009; Cho et al., 2010; Hussain et al., 2012). In this
study, an increase in cytokine expression (e.g., TNF-α and IL-
10) was present in the normotensive CeO2 NP exposed animals
and it has been well established that inflammation is associated
with microvascular dysfunction (Nurkiewicz et al., 2006; LeBlanc
et al., 2009). Furthermore, an increase in TNF-α and IL-10
is associated with the activation of macrophages via toll-like
receptors, which further supports CeO2 NP potential to modify
inflammation (Mosser, 2003). Finally, it should be noted that it
is unclear if CeO2 NP preferentially effect ROS or inflammation
and further studies are needed to address this issue.
Additionally, these changes in inflammatory cytokines and
leukocyte flux could indicate that CeO2 NP modify thrombosis
development. The increase in leukocyte flux in the SH rats
provide indirect evidence for endothelial cell activation, which
results in the production of various adhesion proteins and factors
essential for fibrinolysis (e.g., plasminogen activator inhibitor-1).
Plasminogen activator inhibitor-1 (PAI-1) is secreted by
macrophages, endothelial cells and vascular smooth muscle
cells. Furthermore, this factor is controlled by oxidative stress.
Studies with nano-copper oxide have shown an increase in PAI-
1 secretion following exposure and it is possible that this factor
is also elevated in the SH-Sham rats, thus increasing the risk
of thrombosis (Yu et al., 2010b). However, following CeO2 NP
exposure there is a decrease in leukocyte flux and oxidative stress
in the SH rats, which could indicate a decreased thrombosis risk.
However, the potential increased thromboxane A2 activity (in
the CeO2 NP exposed SH rats) may be linked to the activation
of platelets, which would increase the risk of thrombosis in
these animals. Overall, it appears that CeO2 NP influences the
thrombotic potential in SH rats, but at this time, it is unclear if
they increase or decrease this risk and further studies are needed
to understand these influences.
It should also be noted that there was no microvascular
impairment in the normotensive rats after exposure despite an
increase in pro-inflammatory cytokines. This lack of impairment
maybe due to the time post-exposure (24 h) when reactivity
was assessed and the lack of increased leukocyte adhesion and
rolling in the WKY group further supports this notion. If the
animals were exposed for a longer period of time (over 24 h), an
increase in the activation of adhesion molecules and, ultimately,
leukocyte extravasation may lead to an increase in microvascular
dysfunction and thrombosis development.
Finally, the time of inflammatory assessments may also
contribute to the observed changes in circulating cytokines. TNF-
α is classically considered a pro-inflammatory cytokine that
is involved in macrophage activation, whereas IL-10 is often
considered an anti-inflammatory cytokine because is it capable
of inhibiting TNF-α and IFN-γ (Feghali and Wright, 1997).
In this study, it is possible that at 24 h IL-10 is beginning to
increase, whereas TNF-α may be beginning to decrease, and this
change in expression could result in the brief elevation of both
cytokines. Additionally, based on these results, it is reasonable to
speculate that CeO2 NP may have anti-inflammatory potential
due to the increase in IL-10. Furthermore, SH rats typically have
chronic inflammation, which contributes to their microvascular
dysfunction (Sanz-Rosa et al., 2005). This study showed limited
changes in the expression of pro-inflammatory cytokines in the
SH animals and this lack of cytokine production may due to the
age of the animals used in this study. Additionally, these limited
cytokine and leukocyte results highlight the need for an extensive
time course study to fully understand the effects of CeO2 NP
exposure on inflammation and thrombosis development. Further
studies will need to investigate the relationship between CeO2 NP,
the inflammatory response, and exposure time in normotensive
and hypertensive rats.
In conclusion, this study provides evidence that injected
CeO2 NP decreases microvascular oxidative stress in a high ROS
environment, which in turn, improves microvascular function.
These results further our understanding of CeO2 NP behavior
in vivo and highlight their therapeutic potential as an anti-
oxidant, particularly in pathologies associated with elevated ROS.
Furthermore, this study showed changes in the inflammatory
profile following CeO2 NP exposure. Similarly, it is reasonable
to speculate that CeO2 NP used preemptively would oppose
the acute escalation of local ROS levels associated with various
injuries and treatments. These changes were primarily observed
in the WKY group, which highlight the need for further research
on this ENM in order to understand fully its influences on
systemic inflammation. Fully understanding how CeO2 NP act
in vivo in both low and high ROS environments is critical
for the continued and expanded development of this potential
therapeutic agent.
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